Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.
Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M. Teschendorff AE, et al. Among authors: berns em. Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4. Genome Med. 2015. PMID: 26497652 Free PMC article.
TP53 and ovarian cancer.
Schuijer M, Berns EM. Schuijer M, et al. Among authors: berns em. Hum Mutat. 2003 Mar;21(3):285-91. doi: 10.1002/humu.10181. Hum Mutat. 2003. PMID: 12619114 Free article. Review.
Molecular profiling of platinum resistant ovarian cancer.
Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM. Helleman J, et al. Among authors: berns em. Int J Cancer. 2006 Apr 15;118(8):1963-71. doi: 10.1002/ijc.21599. Int J Cancer. 2006. PMID: 16287073 Free article.
Mismatch repair and treatment resistance in ovarian cancer.
Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM. Helleman J, et al. Among authors: berns em. BMC Cancer. 2006 Jul 31;6:201. doi: 10.1186/1471-2407-6-201. BMC Cancer. 2006. PMID: 16879751 Free PMC article.
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group. Green JA, et al. Among authors: berns em. Eur J Cancer. 2006 Oct;42(15):2539-48. doi: 10.1016/j.ejca.2006.06.015. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16965910 Clinical Trial.
MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. van Jaarsveld MT, et al. Among authors: berns em. Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90. doi: 10.1016/j.biocel.2010.01.014. Epub 2010 Jan 18. Int J Biochem Cell Biol. 2010. PMID: 20083225 Review.
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Vencken PMLH, et al. Among authors: berns em. Ann Oncol. 2011 Jun;22(6):1346-1352. doi: 10.1093/annonc/mdq628. Epub 2011 Jan 12. Ann Oncol. 2011. PMID: 21228333 Free article.
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA. van Jaarsveld MT, et al. Among authors: berns em. Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8. Oncogene. 2013. PMID: 23045278
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group. Despierre E, et al. Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089. Int J Gynecol Cancer. 2014. PMID: 24557434
144 results